A review of international coverage and pricing strategies for personalised medicine and orphan drugs

Health Policy

21 November 2017 - Personalised medicine and orphan drugs share many characteristics—both target small patient populations, have uncertainties regarding efficacy and safety at payer submission, and frequently have high prices. 

Given personalised medicine's rising importance, this review summarises international coverage and pricing strategies for personalised medicine and orphan drugs as well as their impact on therapy development incentives, payer budgets, and therapy access and utilisation.

Read Health Policy review article

Michael Wonder

Posted by:

Michael Wonder